40
original
SUPLEMENTO
Otoneurología 2014:
comprendiendomejor los trastornos vestibulares
Actual.Med.
2014; 99: (791). Supl. 40-60
CONCLUSIONS
VM can result in a significant disabling disorder.
Management of VM includes both symptomatic as well as
prophylactic treatment. There is not a well-established therapy
for VM. Current treatment is based on migraine therapy since
studies that specifically deal with this disease are scarce. Large
prospective, randomized, placebo-controlled clinical trials are
needed. Aswe deepen the pathophysiologicmechanisms of VM
we candevelopamoreprecise therapeutic approach.
REFERENCES
1.
Neuhauser HK, Radtke A, von Brevern M, Feldmann M, Lezius F,
Ziese T, Lempert T. Migrainous vertigo: prevalence and impact on
qualityof life. Neurology2006;67(6):1028-33.
2.
Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey
J, Bisdorff A, Versino M, Evers S, Newman-Toker D. Vestibular
migraine: diagnostic criteria. J VestibRes. 2012;22(4):167-72.
3.
Radtke A, Neuhauser H, von Brevern M, Hottenrott T, Lempert
T. Vestibular migraine--validity of clinical diagnostic criteria.
Cephalalgia. 2011;31(8):906-13.
4.
Batuecas-Caletrio A, Martín-Sanz E, Trinidad-Ruíz G, Espinosa-
Sánchez JM, Alemán-López O. Migraña vestibular: Diagnóstico y
tratamiento. RevSocOtorrinolaringol Castilla LeonCantab LaRioja.
2013;4(5):21-29.
[citado 28 de febrero 2014] dialnet.unirioja.es/
descarga/articulo/4262638.pdf
5.
Sargent EW. The challenge of vestibular migraine. Curr Opin
Otolaryngol HeadNeckSurg. 2013;21(5):473-9.
6.
Furman JM, Marcus DA, Balaban CD. Vestibular migraine: clinical
aspects andpathophysiology. LancetNeurol. 2013;12(7):706-15.
7.
Espinosa-Sánchez JM, López-Escámez JA. Vestibular migraine: an
emergingdiagnosis. ActaOtorrinolaringol Esp. 2013;64(6):387-8.
8.
Lempert T. Vestibularmigraine. SeminNeurol. 2013;33(3):212-8.
9.
BisdorffA.Migraineanddizziness.CurrOpinNeurol.2014;27(1):105-
10.
10. Requena T, Espinosa-Sanchez JM, Lopez-Escamez JA. Genetics of
dizziness: cerebellar and vestibular disorders. Curr Opin Neurol.
2014;27(1):98-104.
11. PietrobonD. Calcium channels andmigraine. BiochimBiophysActa
2013;1828(7):1655-65.
12. Espinosa-Sánchez JM,Martin-Sierra C, Lopez-Escamez JA.Menière
Syndrome and Migraine. In: Colombo B, Teggi R eds. Vestibular
MigraineandRelatedSyndromes. Springer 2014 (inpress).
13. Bikhazi P, Jackson C, Ruckenstein MJ. Efficacy of antimigrainous
therapy in the treatment of migraine-associated dizziness. Am J
Otol. 1997;18(3):350-4.
14. Neuhauser H, Radtke A, von Brevern M, et al. Zolmitriptan for
treatment of migrainous vertigo. A pilot randomized placebo
controlled trial. Neurology2003; 60:882–883.
15. Furman JM,MarcusDA, BalabanCD. Rizatriptan reducesvestibular-
induced motion sickness in migraineurs. J Headache Pain.
2011;12(1):81-8.
16. Raike RS, Weisz C, Hoebeek FE, Terzi MC, De Zeeuw CI, van
den Maagdenberg AM, Jinnah HA, Hess EJ. Stress, caffeine and
ethanol trigger transient neurological dysfunction through shared
mechanisms in a mouse calcium channelopathy. Neurobiol Dis.
2013;50:151-9.
17. Johnson GD. Medical management of migraine-related dizziness
and vertigo. Laryngoscope. 1998 Jan;108(1Pt 2):1-28.
18. Reploeg MD, Goebel JA. Migraine-associated dizziness: patient
characteristics and management options. Otol Neurotol
2002;23:364–371.
19. MikulecAA, Faraji F,KinsellaLJ. Evaluationof theefficacyof caffeine
cessation, nortriptyline, and topiramate therapy in vestibular
migraine and complex dizziness of unknown etiology. Am J
Otolaryngol. 2012;33(1):121-7.
20. Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine
prophylaxis: a randomized studyusing relaxationand topiramateas
controls. Cephalalgia. 2011;31(14):1428-38.
21. Maione A. Migraine-Related Vertigo: Diagnostic criteria and
prophylactic treatment. Laryngoscope2006;116:1782-6.
22. Baier B, Winkenwerder E, Dieterich M. “Vestibular migraine”:
effects of prophylactic therapywith various drugs. A retrospective
study. JNeurol. 2009;256(3):436-42.
23. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of
cortical spreading depression inmigraine prophylaxis. AnnNeurol.
2006;59(4):652-61.
24. LindeM,MullenersWM, ChronicleEP,McCroryDC. Topiramate for
the prophylaxis of episodicmigraine in adults. Cochrane Database
Syst Rev. 2013;6:CD010610.
25. Linde M, Mulleners WM, Chronicle EP, McCrory DC Valproate
(valproic acidor sodium valproateor a combinationof the two) for
the prophylaxis of episodicmigraine in adults. Cochrane Database
Syst Rev. 2013;6:CD010611.
26. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman
E; Quality Standards Subcommittee of the American Academy of
Neurology and the American Headache Society. Evidence-based
guideline update: pharmacologic treatment for episodic migraine
prevention inadults: reportof theQualityStandardsSubcommittee
of theAmericanAcademyofNeurologyandtheAmericanHeadache
Society. Neurology2012;78(17):1337-45.
27. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS;
European Federation of Neurological Societies. EFNS guideline on
the drug treatment of migraine--revised report of an EFNS task
force. Eur JNeurol. 2009;16(9):968-81.
28. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin
or pregabalin for the prophylaxis of episodic migraine in adults.
CochraneDatabaseSyst Rev. 2013; 24;6:CD010609.
29. LindeM, MullenersWM, Chronicle EP, McCrory DC. Antiepileptics
other than gabapentin, pregabalin, topiramate, and valproate for
the prophylaxis of episodicmigraine in adults. Cochrane Database
Syst Rev. 2013 Jun24;6:CD010608.
30. CarmonaS,SettecaseN.UseofTopiramate (Topamax) inaSubgroup
of Migraine–Vertigo Patients with Auditory Symptoms. Ann. N.Y.
Acad. Sci. 2005;1039: 517–520.
31. GodeS,CelebisoyN,Kirazli T,AkyuzA,BilgenC,KarapolatH, SirinH,
GokcayF.Clinical assessmentof topiramate therapy inpatientswith
migrainous vertigo. Headache2010;50(1):77-84.
32. Gordon CR, Kuritzky A, Doweck I, Spitzer O, Shupak A, Hering R.
Vestibulo-ocular reflex in migraine patients: the effect of sodium
valproate. Headache. 1993;33(3):129-32.
33. CelikerA,BirLS,ArdiçN.Effectsofvalproateonvestibularsymptoms
and electronystagmographic findings in migraine patients. Clin
Neuropharmacol 2007;30(4):213-7.
34. Bisdorff AR. Management of vestibular migraine. Ther Adv Neurol
Disord. 2011;4(3):183-91.
35. BisdorffAR. Treatment ofmigraine relatedvertigowith lamotrigine
anobservational study. Bull Soc SciMedGrandDuche Luxembourg
2004;(2):103-8.
36. Pringsheim T, Davenport W, Mackie G, Worthington I, Aubé M,
Christie SN, Gladstone J, Becker WJ; Canadian Headache Society
Prophylactic Guidelines Development Group. Canadian Headache
Society guideline for migraine prophylaxis. Can J Neurol Sci.
2012;39(2Suppl 2):S1-59.
37. Cherchi M, Hain TC. Migraine-associated vertigo. Otolaryngol Clin
NorthAm.2011;44(2):367-75.
38. StruppM, Kremmyda O, Brandt T. Pharmacotherapy of vestibular
disorders andnystagmus. SeminNeurol. 2013;33(3):286-96.
39. Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A.
Flunarizine in the prophylaxis ofmigrainous vertigo: a randomized
controlled trial. EurArchOtorhinolaryngol. 2013Oct 29. [inpress]
40. Iwasaki S, Ushio M, Chihara Y, Ito K, Sugasawa K, Murofushi T.
Migraine-associated vertigo: clinical characteristics of Japanese
patients and effect of lomerizine, a calcium channel antagonist.
ActaOtolaryngol Suppl. 2007;(559):45-9.
41. Baloh RW, Jacobson K, Fife T. Familial vestibulopathy: a new
dominantly inherited syndrome. Neurology. 1994;44(1):20-5.
42. Baloh RW, Foster CA, Yue Q, Nelson SF. Familial migraine with
vertigoandessential tremor. Neurology. 1996Feb;46(2):458-60.
